H.C. Wainwright raised the firm’s price target on Greenwich LifeSciences to $38 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm believes the company may need to raise additional capital within the next 12 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI:
- Greenwich LifeSciences provides update on FLAMINGO-01 trial
- Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
- Greenwich LifeSciences Set to Join Russell 2000 Index Again
- Greenwich LifeSciences set to join Russell 2000 Index
- Fly Insider: Occidental, Applied Materials among week’s notable insider trades